|
重庆前沿生物 研发全球唯一长效抗艾药
来源：重庆商报 2010年12月08日02:18
 |
| 图示∶2010年12月即将出版的《中国特色医疗金鉴》登载的刘君主任及其机构 |
| |
|
|
重庆前沿生物技术生物有限公司没有豪华的设备和厂房，核心团队却是全球一流的药学精英，而且在没有任何盈利的情况下，这些科研人员埋头苦干了8年。由前沿生物研发的拥有全球专利的抗击艾滋病新药艾博卫泰，已经在北京一家医院进入临床二期，预计2012年正式上市，成为我国首个自主研发的抗艾新药。
前沿生物研发的具有全球专利的I类创新药物艾博卫泰，是目前世界唯一的长效抗艾滋病新药，具有安全性高、药效强、治疗方便等多方面的全球竞争优势。该产品上市，将填补中国抗癌新药的空白。与目前国外上市的同类产品相比，艾博卫泰还具有鲜明的特点和市场竞争力。“同类产品一天需要打两针，我们的产品两个星期只需要打一针。不仅长效，并且对成本控制效果明显。”前沿生物首席商务官王冒进说。
据了解，目前该药的研制已经投入了数千万元，启动三期临床后，还将投入1亿元左右。
从2002年公司成立，到2012年新药上市，花费的时间将长达10年。但这些付出不会白费。艾博卫泰计划于2012年投放中国市场，保守估计当年销售额可以达1亿元；第二年可跃升至2亿～3亿元。前沿生物还将和国外制药企业联合开发欧美市场。此外，非洲地区拥有2300万名艾滋病感染者，这将是艾博卫泰的重要市场，年销售额可达到10亿元以上。
记者了解到，前沿生物的核心团队成员几乎是清一色的博士。董事长谢东是美国约翰霍普金斯大学理学博士、博士后，首席执行官姜和是医学博士、理学博士，首席商务官王昌进则是肯塔基大学药学院的理学博士。
2010年10月，前沿生物成为中国首家院士工作站单位。著名病毒专家、中国科学院曾毅院士和北京佑安医院院长、知名临床医学专家金荣华教授成为首批院士专家。这个重庆首家与企业联姻的院士工作站，将企业的创新研发能力与国内顶尖科学技术资源相结合，成为提升核心竞争力的“新引擎”。记者 陈柯
Chongqing, the only long-lasting cutting edge biological research Kangai Yao
Source: Chongqing Business Daily at 2:18 on December 8, 2010
Biological Co., Ltd. in Chongqing is not cutting-edge biotechnology equipment and luxurious plants, the core team is the elite world-class medicine, and in the absence of any profit, these researchers work hard for 8 years. Owned by the cutting-edge biological research and development of new drugs to fight AIDS worldwide patents Aibo Wei Tai, has been in a Beijing hospital in clinical Phase II, expected to be officially listed in 2012, becoming China's first self-developed anti-AIDS drugs.
Forefront of biological research and development of a global class of innovative medicines patented I Aibo Wei-tai, is the world's only long-acting anti-AIDS drugs, with high safety, high efficacy, treatment convenience, and many other global competitive advantage. The market, China's anti-cancer drugs will fill the gaps. With the current foreign market compared to similar products, Abbott Methodist Thailand also has distinct characteristics and market competitiveness. "Similar products require two injections a day, our products are only shot for two weeks. Not only long-lasting and significant effect on cost control." Cutting edge aggressive biological Chief Commercial Officer, said the king.
It is understood that the present development of the drug has invested tens of millions, after the start of clinical Phase III, will invest 1 billion yuan.
Founded in 2002, 2012, new drugs, the time will be up to 10 years. But these pay will be fruitful. Abbot David Thai in 2012 for the China market, a conservative estimate when the annual sales could reach 100 million yuan; the second year jumped to 200 million to 3 million. Forefront of biological and foreign pharmaceutical companies will also jointly develop European markets. In addition, Africa has 23 million AIDS infected people, this will be an important market for Thai satellite Aibo, annual sales could reach 10 billion yuan.
This reporter learned that the core of cutting-edge biological almost all team members, Dr. Xie Dong, chairman of the U.S. Johns Hopkins University, Ph.D., postdoctoral fellows, ginger and is CEO of MD, Ph.D., Chief Commercial Officer, Chang-Jin is the University of Kentucky College of Pharmacy Doctor of Science.
October 2010, the first Chinese Academy of cutting-edge bio-workstation units. Leading virus experts, Zeng Yi, Chinese Academy of Sciences Academy of Sciences and Beijing You An Hospital, well-known clinical experts, Professor Jin Ronghua be among the first academicians and experts. The marriage of Chongqing, the first academicians and business workstations, the company's top domestic R & D capabilities and resources of science and technology combine to enhance the core competitiveness to become the "new engine." Reporter Chen Ke
|
